Immune checkpoint inhibitor–associated capillary leak syndrome: A systematic review and a worldwide pharmacovigilance study
Journal of Internal Medicine · 2023-07 · 294 (1) · 58-68
DOI: 10.1111/joim.13641 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Internal Medicine, online erschienen am 20.04.2023. Verfasst von Jonathan Wong So und 5 weiteren Autor:innen. Beteiligte Einrichtung: CHR d'Orléans, Service de Médecine Interne, Orléans, France. Hauptthemen laut MEDLINE: Capillary Leak Syndrome, Antineoplastic Agents, Immunological, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Although a few case reports have shown that immune checkpoint inhibitors (ICIs) are potential inducers of capillary leak syndrome (CLS), an incidental finding cannot be ruled out. The aim of this study was to describe the clinical characteristics of ICI‐induced CLS through a systematic review and to assess a potential safety signal.
Methods
Medline/PubMed, Embase, and Reactions Weekly were screened, and a global disproportionality study was performed using the World Health Organization pharmacovigilance database through January 15, 2023. A signal of disproportionate reporting was defined as a Bayesian information component (IC) with a 95% credibility interval (CrI) lower boundary that exceeds 0.
Results
A total of 47 cases of ICI‐associated CLS were included, 14 from the systematic review (of 61 screened articles) and 33 from VigiBase (of 34,058,481 reports of adverse drug reactions). The median time to CLS onset from the start of ICI was 12 weeks (interquartile range 8–49, n = 24). A total of 57% (8/14) of patients experienced an immune‐related adverse event (irAE) before CLS. A fatal outcome was reported in 23% (7/31) of patients. A significant overreporting of CLS was found with ICIs compared with all other drugs (IC 2.4, 95% CrI from 1.8 to 2.8).
Conclusion
This study showed a significant signal of disproportionality reporting for ICI‐induced CLS, characterized by a long time to onset, and compared with the idiopathic form of the disease with a less abrupt onset and a less consistent hemoconcentration pattern.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CHR d'Orléans, Service de Médecine Interne, Orléans, France.
- CHR d'Orléans, Service de Médecine-Intensive Réanimation, Orléans, France.
- CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours, France.
- CHRU de Tours, Service de Médecine Interne et Immunologie Clinique, Tours, France.
ORCID-Profile: Jonathan Wong So, Annie-Pierre Jonville-Béra, François Maillot, Bérenger Largeau
Zitieren
APA
Wong So, J., Bouibede, F., Jonville-Béra, A. P., Maillot, F., Barbier, F., & Largeau, B. (2023). Immune checkpoint inhibitor–associated capillary leak syndrome: A systematic review and a worldwide pharmacovigilance study. Journal of Internal Medicine, 294(1), 58-68. https://doi.org/10.1111/joim.13641
Vancouver
Wong So J, Bouibede F, Jonville-Béra AP, Maillot F, Barbier F, Largeau B. Immune checkpoint inhibitor–associated capillary leak syndrome: A systematic review and a worldwide pharmacovigilance study. Journal of Internal Medicine. 2023;294(1):58-68. doi:10.1111/joim.13641
BibTeX
@article{WongSo2023,
author = {Wong So, Jonathan and Bouibede, Fatma and Jonville-Béra, Annie-Pierre and Maillot, François and Barbier, François and Largeau, Bérenger},
title = {Immune checkpoint inhibitor–associated capillary leak syndrome: A systematic review and a worldwide pharmacovigilance study},
journal = {Journal of Internal Medicine},
year = {2023},
volume = {294},
number = {1},
pages = {58--68},
doi = {10.1111/joim.13641}
}
EUVIMED